Phase II trial of Rituxan [rituximab] plus FavId (tumor-specific idiotype-KLH) [mitumprotimut T] and GM-CSF [granulocyte-macrophage colony-stimulating factors] immunotherapy in patients with grade 1 or 2 follicular B-cell lymphoma.

Trial Profile

Phase II trial of Rituxan [rituximab] plus FavId (tumor-specific idiotype-KLH) [mitumprotimut T] and GM-CSF [granulocyte-macrophage colony-stimulating factors] immunotherapy in patients with grade 1 or 2 follicular B-cell lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2011

At a glance

  • Drugs Mitumprotimut T; Rituximab; Sargramostim
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2007 Four-year follow-up results to be reported at ASH 2007.
    • 10 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top